RPG Life Sciences Limited

RPGLIFE: Investor Presentation on Unaudited Financial Results for Quarter Ended December 31, 2025

RPG Life Sciences released its investor presentation for the quarter ended December 31, 2025. Q3 FY26 revenue was ₹180 crore, up from ₹172.7 crore in Q3 FY25. EBITDA was ₹43.2 crore with a 24.0% margin. The company's long-term credit rating has been reaffirmed at A+ with a stable outlook, and the short-term rating at A1 by ICRA. The company aims to grow its immunosuppressant portfolio to over ₹200 crore.

RPG Life Sciences Q3 FY26 Investor Presentation Released

RPG Life Sciences released its Q3 FY26 investor presentation. For Q3 FY26, revenue was ₹180.0 crore. For 9M FY26, revenue reached ₹530.6 crore. Domestic Formulations contributed 71% to sales. The company is focused on building mega brands, expanding API business, and pursuing M&A, with ₹140 crore capex invested since FY22.

RPG Life Sciences Q3 FY26 Revenue Up 4.2% YoY to ₹180 Cr; EBITDA Margin at 24%

RPG Life Sciences reported Q3 FY26 revenue of ₹180.0 crores, a 4.2% year-on-year increase. The company maintained an EBITDA margin of 24.0%. For 9M FY26, revenue grew 4.0% year-on-year to ₹530.6 crores. The Domestic Formulations business showed growth of 11.8% in 9M FY26, outpacing the Indian Pharmaceutical Market.

RPG Life Sciences Board Approves Q3 FY26 Unaudited Financial Results

RPG Life Sciences board approved unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The board meeting was held on January 27, 2026.

RPG Life Sciences Board Approves Q3 FY26 Unaudited Financial Results

RPG Life Sciences' Board approved the unaudited financial results for the quarter and nine months ended December 31, 2025. The results included both standalone and consolidated figures. The board meeting took place on January 27, 2026.

RPG Life Sciences: Certificate of Compliance Filed Under SEBI Regulations

RPG Life Sciences Limited received a compliance certificate from its Registrar and Transfer Agents, MUFG Intime India Private Limited. The certificate confirms adherence to SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2025, regarding the dematerialisation of securities.

RPG Life Sciences: Newspaper Notice for Share Transfer Window

RPG Life Sciences Limited has published a newspaper notice regarding a special window for re-lodging physical share transfer requests, as per SEBI guidelines. The notice appeared in Business Standard and Mumbai-Lakshadeep.

RPG Life Sciences Receives GST Order: ₹1.08 Crore Demand

RPG Life Sciences received a GST order for the tax period April 2021-March 2022. The total demand includes ₹52.85 lakh tax, ₹44.40 lakh interest, and ₹10.57 lakh penalty, amounting to ₹1.08 crore. The company plans to contest the demand and does not foresee a material financial impact.

RPG Life Sciences Incorporates Wholly Owned Subsidiary 'RPG Active Pharma Limited'

RPG Life Sciences Limited incorporated a wholly owned subsidiary, RPG Active Pharma Limited, on December 24, 2025. This follows previous disclosures made on December 15, 2025, regarding the subsidiary's establishment.

RPG Life Sciences: Trading Window Closed Jan 1, 2026, for Q3 FY26 Results

RPG Life Sciences will close its trading window from January 1, 2026, until 48 hours after the declaration of Q3 FY26 unaudited financial results. The board meeting date for results declaration will be announced later.

RPG Life Sciences: Board Authorizes KMPs for Materiality Disclosures

RPG Life Sciences' Board authorized MD Ashok Nair and CFO Amol Lone to jointly determine event materiality from Dec 15, 2025. Nair, Lone, and Head-Legal & Company Secretary Rajesh Shirambekar are severally authorized for stock exchange disclosures. Shirambekar is the single point of contact.

RPG Life Sciences Appoints New CFO, Transfers API Business to Subsidiary

RPG Life Sciences appointed Amol Lone as CFO and KMP, effective December 15, 2025. The company will incorporate a wholly owned subsidiary, "RPG Active Pharma Limited", to house its API business. The API business, contributing ₹90.24 crore revenue, will be transferred for an estimated ₹50 crore. RPG Life Sciences will invest up to ₹105 crore in the subsidiary.

RPG Life Sciences Appoints New CFO, Transfers API Business to Subsidiary

RPG Life Sciences appointed Mr. Amol Lone as CFO effective December 15, 2025. The company will incorporate "RPG Active Pharma Limited" to house its API business, transferring it for an estimated ₹50 crore. Up to ₹105 crore will be invested in the subsidiary. The transfer is expected to be completed by March 31, 2026.

RPG Life Sciences Appoints New CFO, Forms Subsidiary, Transfers API Business

RPG Life Sciences appointed Amol Lone as CFO. The company will incorporate a wholly owned subsidiary, RPG Active Pharma Limited, to focus on API business. The API business will be transferred to this subsidiary for an estimated ₹50 crore. RPG Life Sciences will invest up to ₹105 crore in the new subsidiary.

RPGLIFE Receives Order from GST Authority, Gujarat

RPG Life Sciences received an order from GST Authority, Gujarat for ₹2.04 crore related to tax period April 2021 - March 2022. The company will seek legal remedy and does not foresee material financial impact.

RPGLIFE: Newspaper Publication for Physical Share Transfer Re-lodgement

RPG Life Sciences published a reminder notice on November 15, 2025, regarding the special window for re-lodgement of physical share transfer requests, following earlier intimations and a SEBI circular.

Transcript of Q2 FY26 Results Earnings Call Available

RPGLIFE announces that the transcript of the Q2 FY26 results earnings call held on October 17, 2025, is available on the company's website.

RPGLIFE Responds to NSE Regarding Increase in Volume

RPG Life Sciences responded to NSE's inquiry regarding a volume increase, stating no undisclosed events or information impacting performance and affirming commitment to timely disclosures.

RPGLIFE: Audio Recording of Q2 FY26 Results Earnings Call

RPGLIFE announces that the audio recording of its Q2 FY26 earnings call held on October 17, 2025, is available on the company's website. The transcript will be uploaded subsequently.

RPGLIFE: Newspaper Publication of Unaudited Financial Results

RPG Life Sciences published unaudited financial results for the quarter and half year ended September 30, 2025, in newspapers and on its website, complying with SEBI regulations.

RPG Life Sciences Reports Strong Q2 FY26 Results; CFO Vishal Shah Resigns, Effective Oct 23

RPG Life Sciences reported strong Q2 FY26 results with ₹3,685 lakhs profit. CFO Vishal Shah resigned, effective Oct 23, 2025. Fire incident loss partially recovered by insurance.

RPG Life Sciences Reports Strong Q2 FY26 Results with 7.6% Q-o-Q Revenue Growth

RPG Life Sciences reported Q2 FY26 revenue up 7.6% Q-o-Q to ₹181.7 crore, with EBITDA margin at 24.0%. Domestic formulations outperformed the market.

RPGLIFE Announces Investor Presentation for Quarter Ended September 30, 2025

RPG Life Sciences Limited releases investor presentation on unaudited financial results for the quarter and half year ended September 30, 2025.

RPGLIFE Announces CFO Resignation, and Unaudited Financial Results

RPG Life Sciences announced CFO Vishal Shah's resignation effective Oct 23, 2025, and approved unaudited financial results for the quarter ended September 30, 2025, with revenue at ₹18,168 lakhs.

RPG Life Sciences Board Approves Q2/H1 FY26 Results; CFO Vishal Shah Resigns

RPG Life Sciences announced Q2/H1 FY26 results with increased profits. CFO Vishal Shah resigned, effective October 23, 2025. The company also detailed the financial impact and insurance recovery of a fire incident.

RPG Life Sciences to Host Q2 FY26 Earnings Call on October 17, 2025

RPG Life Sciences will host its Q2 FY26 earnings call on October 17, 2025, to discuss financial results for the quarter and half-year ended September 30, 2025.

RPGLIFE Announces Earnings Call for Quarter Ended September 30, 2025

RPG Life Sciences announces an earnings call on October 17, 2025, at 7:00 p.m. IST to discuss the unaudited financial results for the quarter ended September 30, 2025. Dial-in details are provided.

RPG Life Sciences Submits SEBI Regulation 74(5) Compliance Certificate for Q2 FY26

RPG Life Sciences submitted a certificate from MUFG Intime India Private Limited confirming compliance with SEBI Regulation 74(5) for the quarter ended September 30, 2025, regarding dematerialisation of securities.

RPGLIFE: 'Saksham Niveshak' Campaign for Shareholders' KYC & Unclaimed Dividends

RPGLIFE to participate in Antique's Flagship Investor Conference 2025

RPG Life Sciences Board Approves Unaudited Financial Results and Policy Revision

RPGLIFE Announces Q1 FY26 Results; Focus on Growth and Expansion

RPG Life Sciences Appoints Deepak Shukla as Chief Executive - API Business

RPG Life Sciences Reports Q1 FY26 Results: Revenue Up 2.1% Y-o-Y, EBITDA Margin at 24.1%